Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
US Army
Harvard Business School
Federal Trade Commission
Fuji
Medtronic
Cipla
UBS
Boehringer Ingelheim

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075536

« Back to Dashboard
NDA 075536 describes DOXAZOSIN MESYLATE, which is a drug marketed by Mylan, Nesher Pharms, Zydus Pharms Usa Inc, Accord Hlthcare, Watson Labs Inc, Idt Australia Ltd, Teva, Sandoz, Pliva, Ivax Sub Teva Pharms, Dava Pharms Inc, Genpharm, Actavis Elizabeth, and Apotex, and is included in fifteen NDAs. It is available from thirty-three suppliers. Additional details are available on the DOXAZOSIN MESYLATE profile page.

The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There are thirteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

Summary for NDA: 075536

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Genitourinary Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 075536

Mechanism of ActionAdrenergic alpha-Antagonists

Suppliers and Packaging for NDA: 075536

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOXAZOSIN MESYLATE
doxazosin mesylate
TABLET;ORAL 075536 ANDA Teva Pharmaceuticals USA, Inc. 0093-2067 0093-2067-01 100 TABLET in 1 BOTTLE (0093-2067-01)
DOXAZOSIN MESYLATE
doxazosin mesylate
TABLET;ORAL 075536 ANDA Teva Pharmaceuticals USA, Inc. 0093-2068 0093-2068-01 100 TABLET in 1 BOTTLE (0093-2068-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Oct 18, 2000TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2MG BASE
Approval Date:Oct 18, 2000TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Oct 18, 2000TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cipla
Argus Health
AstraZeneca
Mallinckrodt
UBS
US Department of Justice
Cerilliant
Boehringer Ingelheim
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot